Edwards Lifesciences Corporation
EW
$85.98
-$1.56-1.78%
NYSE
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 1.65B | 1.57B | 1.55B | 1.53B | 1.41B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.65B | 1.57B | 1.55B | 1.53B | 1.41B |
| Cost of Revenue | 362.60M | 343.00M | 345.20M | 344.40M | 301.60M |
| Gross Profit | 1.29B | 1.23B | 1.21B | 1.19B | 1.11B |
| SG&A Expenses | 522.20M | 601.20M | 514.60M | 502.00M | 465.70M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -14.20M | -14.30M | -12.50M | -21.30M | -19.10M |
| Total Operating Expenses | 1.13B | 1.20B | 1.13B | 1.10B | 1.00B |
| Operating Income | 514.70M | 372.00M | 425.10M | 430.90M | 409.90M |
| Income Before Tax | 459.00M | 90.40M | 348.40M | 400.20M | 433.90M |
| Income Tax Expenses | 78.30M | 26.20M | 56.10M | 64.30M | 70.30M |
| Earnings from Continuing Operations | 380.70M | 64.20M | 292.30M | 335.90M | 363.60M |
| Earnings from Discontinued Operations | -- | 27.00M | -2.00M | -4.40M | -7.20M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | 0.00 | 800.00K | 1.70M | 1.60M |
| Net Income | 380.70M | 91.20M | 291.10M | 333.20M | 358.00M |
| EBIT | 514.70M | 372.00M | 425.10M | 430.90M | 409.90M |
| EBITDA | 555.60M | 414.70M | 464.30M | 469.00M | 446.50M |
| EPS Basic | 0.66 | 0.16 | 0.50 | 0.57 | 0.61 |
| Normalized Basic EPS | 0.65 | 0.50 | 0.48 | 0.43 | 0.46 |
| EPS Diluted | 0.66 | 0.15 | 0.50 | 0.56 | 0.61 |
| Normalized Diluted EPS | 0.65 | 0.50 | 0.48 | 0.43 | 0.46 |
| Average Basic Shares Outstanding | 579.20M | 580.40M | 584.70M | 587.00M | 586.90M |
| Average Diluted Shares Outstanding | 580.70M | 581.80M | 585.70M | 587.90M | 587.80M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |